CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nymox Pharmaceutical Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nymox Pharmaceutical Corp
St. Laurent,Suite 306
9900 Cavendish Blvd
Phone: 800-9369669p:800-9369669 SAINT-LAURENT, QC  H4M 2V2  Canada Ticker: NYMXFNYMXF
Business Summary
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NYMOZARFEX, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company also has a patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. It also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke.
(Source: PROXY)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer PaulAverback 74 1/1/2006 9/20/1995
Vice President, General Counsel, Director PatrickDoody 7/12/2023 7/12/2023
Independent Director DavidMorse 67 6/8/2006 6/8/2006
Independent Director James G.Robinson 88 12/17/2015 12/17/2015

Business Names
Business Name
Nymox Pharmaceutical Corporation
NYMX
NYMXF

General Information
Number of Employees: 3 (As of 12/31/2021)
Outstanding Shares: 93,450,000 (As of 11/12/2024)
Shareholders: 5,366
Stock Exchange: OTC
Fax Number: 514-3322227
Email Address: info@nymox.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024